Sandip Kapadia Sells 3,746 Shares of Harmony Biosciences (NASDAQ:HRMY) Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) CFO Sandip Kapadia sold 3,746 shares of Harmony Biosciences stock in a transaction on Monday, January 26th. The shares were sold at an average price of $37.15, for a total value of $139,163.90. Following the completion of the sale, the chief financial officer directly owned 24,521 shares of the company’s stock, valued at $910,955.15. The trade was a 13.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Sandip Kapadia also recently made the following trade(s):

• On Thursday, January 15th, Sandip Kapadia sold 20,961 shares of Harmony Biosciences stock. The shares were sold at an average price of $35.92, for a total value of $752,919.12.

Harmony Biosciences Trading Down 2.2%

NASDAQ HRMY traded down $0.84 during trading on Wednesday, hitting $36.84. The stock had a trading volume of 503,087 shares, compared to its average volume of 597,958. The company has a quick ratio of 3.72, a current ratio of 3.75 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $2.12 billion, a PE ratio of 11.58, a PEG ratio of 0.35 and a beta of 0.84. The firm has a 50 day moving average price of $37.30 and a 200 day moving average price of $34.23. Harmony Biosciences Holdings, Inc. has a twelve month low of $25.52 and a twelve month high of $40.87.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $0.87 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.05). Harmony Biosciences had a net margin of 22.50% and a return on equity of 24.88%. The business had revenue of $239.46 million during the quarter, compared to analysts’ expectations of $222.68 million. As a group, equities research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Hedge Funds Weigh In On Harmony Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HRMY. Amundi raised its holdings in Harmony Biosciences by 115.6% during the first quarter. Amundi now owns 39,668 shares of the company’s stock worth $1,229,000 after purchasing an additional 21,266 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Harmony Biosciences by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,651 shares of the company’s stock valued at $752,000 after buying an additional 984 shares during the last quarter. Empowered Funds LLC acquired a new stake in Harmony Biosciences during the 1st quarter worth $2,330,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Harmony Biosciences by 53.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 95,389 shares of the company’s stock worth $3,166,000 after acquiring an additional 33,058 shares in the last quarter. Finally, State of Alaska Department of Revenue lifted its position in Harmony Biosciences by 8.1% in the second quarter. State of Alaska Department of Revenue now owns 22,897 shares of the company’s stock valued at $722,000 after acquiring an additional 1,724 shares during the last quarter. 86.23% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently issued reports on HRMY shares. Mizuho lifted their target price on Harmony Biosciences from $39.00 to $46.00 and gave the company an “outperform” rating in a report on Monday, December 1st. HC Wainwright reiterated a “buy” rating on shares of Harmony Biosciences in a research note on Wednesday, December 3rd. Truist Financial lowered their price objective on Harmony Biosciences from $48.00 to $45.00 and set a “buy” rating for the company in a research report on Thursday, January 8th. UBS Group reduced their target price on shares of Harmony Biosciences from $50.00 to $43.00 and set a “buy” rating on the stock in a report on Wednesday, October 15th. Finally, Wall Street Zen upgraded shares of Harmony Biosciences from a “hold” rating to a “buy” rating in a research note on Saturday, December 13th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $45.25.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.